DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-396

Wyeth Pharmaceuticals
Attention: Jennifer D. Norman, RPh
Associate Director, Worldwide Regulatory Affairs
P.O. Box 8299
Philadelphia, PA 19101-8299

Dear Ms. Norman:

Please refer to your new drug application (NDA) dated September 24, 2001, received September 25, 2001, submitted under Section 505b(1) of the Federal Food, Drug, and Cosmetic Act for Prempro™/Premphase® (conjugated estrogens/medroxyprogesterone acetate tablets) 0.45mg/1.5mg and 0.3mg/1.5mg.

We acknowledge receipt of your submissions dated November 18, December 3, 2002, April 2, and May 30, 2003.

The December 3, 2002 submission constituted a complete response to our July 25, 2002 action letter.

This new drug application provides for the use of Prempro™/Premphase® (conjugated estrogens/medroxyprogesterone acetate tablets) 0.45mg/1.5mg and 0.3mg/1.5mg for the prevention of postmenopausal osteoporosis.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (package insert and patient package insert) and submitted labeling, (immediate container and carton labels submitted September 24, 2001). Marketing the products with FPL that is not identical to the approved labeling text may render the products misbranded and unapproved new drugs.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 21-396**." Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for these products. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Metabolic and Endocrine Drug Products and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA (NDA 20-527). In the future, do not make submissions to this NDA except for the final printed labeling requested above.

If you have any questions, call Pat Madara, Regulatory Project Manager, at (301) 827-6416.

Sincerely,

{See appended electronic signature page}

David G.Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosures: package insert
patient package insert

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff
6/4/03 04:03:24 PM